ITPD20090021A1 - MEDICAL AND / OR FOOD AND / OR FOOD AND / OR PROBIOTIC SUPPLEMENT AND / OR HOMEOPATHIC PRODUCT WITH LISATES AND / OR TINDALIZED OF PHYSIOLOGICAL, LYSATED AND / OR TINDALIZED BACTERIA OF PHYSIOLOGICAL, LYSATED AND / OR TINDALIZED MICROBIAL FISIOL - Google Patents

Description

MEDICINAL AND / OR FOOD PRODUCT AND / OR SUPPLEMENT

FOOD AND / OR PROBIOTIC

AND / OR HOMEOPATHIC PRODUCT WITH LYSATES AND / OR THINDALISED

OF PHYSIOLOGICAL BACTERIA, LYSATES AND / OR THINDALISED OF

PHYSIOLOGICAL MYCETES, LYSATES AND / OR TINDALISED OF SPORES

PHYSIOLOGICAL MICROBIALS

DESCRIPTION

This patent relates to medicinal and / or food products and / or food supplements and / or probiotics and / or homeopathic products for the balance of intestinal bacterial flora and / or for the treatment and / or adjuvant of disorders of the Gastrointestinal system, genitourinary system, for the immune defenses and in particular it concerns a new type of medicinal and / or food product and / or supplement, with lysates and / or tindalized, obtained chemically and / or mechanically and / or physical, of bacteria, fungi, microbial spores, physiological or of all the species that populate the microflora of the gastro-intestinal system and which have beneficial effects for the balance of the intestinal bacterial flora, for the balance of the flora urogenital bacterial, for the balance of the oral bacterial flora and for disorders in general affecting the gastrointestinal tract of the genitourinary, oral and respiratory mucous membranes and to stimulate the immune defenses.

Disorders caused by alterations in the balance of the intestinal and vaginal bacterial flora are known, which constitutes the first barrier against infections and contributes to maintaining the good state of health of men.

The intestinal microflora is mainly composed of anaerobic bacteria, such as Bacteriumids and Bifidobacteria, and also of aerobic bacteria, such as Clostridia, Lactobacilli, etc. In the intestine there are also viruses, fungi, ie fungi and yeasts, and a large amount of protozoa.

The intestinal bacterial microflora attacks foreign pathogenic microorganisms and thus performs a very important immune function.

Alterations of the intestinal bacterial flora cause various pathologies and functional disorders of the gastrointestinal system, as well as alterations of the immune and respiratory systems.

Another important consequence of said intestinal bacterial flora imbalances is the appearance of food allergies and intolerances and / or adverse reactions to food.

The alteration of the bacterial flora is also involved in the development of chronic candidiasis, with colonization of the intestinal mucosa and genitourinary mucosa.

The causes of alteration of the intestinal and vaginal bacterial flora are numerous.

One of the main factors is the incorrect diet. For example, the lack of fiber and the excessive intake of sugars, dyes, preservatives, etc. are among the major causes of alterations in the balance of the bacterial flora as well as an alteration of circadian rhythms, see stress, and poor digestion .

Another factor of fundamental importance is the abuse of antibiotics and sulfonamides which, with their bactericidal or bacteriostatic load, also act on the resident bacteria, ie on said bacterial flora.

The subject of this patent is a new type of medicinal and / or food product and / or food supplement and / or probiotic and / or homeopathic product, with lysates and / or tindalised bacteria, lysates and / or tindalised mycetes, and in particular with lysates and / or tindalized physiological bacteria or lysates and / or tindalized lactic ferments, lysates and / or tindalized saccharomycetes and yeasts, to restore and / or maintain the balance of intestinal bacterial flora and vaginal bacterial flora and for the treatment of disorders in general affecting the gastrointestinal tract, genitourinary mucosa, respiratory tract and IgE mediated and non-mediated allergic manifestations.

The main task of the present invention is to maintain and / or restore the balance of the intestinal bacterial flora and the vaginal bacterial flora and to reduce the inflammatory processes affecting any part of the body that directly or indirectly are a consequence and / or in relation to a disturbance and / or imbalance of the gastrointestinal system and / or its colonization (eubiosis) and / or immunological or inflammatory alterations secondary to alteration of intestinal flora.

Another object of the present invention is to favor and / or modulate and / or activate and / or inhibit the response and reaction of the immune system of the gastrointestinal tract and of the genitourinary mucosa.

Another object of the present invention is to facilitate and / or inhibit the development of certain microbial strains and the reaction of the surface receptors of the mucous membranes, to simulate a local or systemic response towards the strains used, in order to reactivate and re-establish a correct reaction. immunological of the self - non self type against these strains which, physiologically, over time, colonize and regulate the intestinal environment starting from birth.

Another purpose of the present invention is to strengthen the immune system.

Another object of the present invention is to stimulate an immune response to disorders affecting the gastrointestinal tract and genitourinary mucosa, without and / or with the aid of antibiotic medicines.

These and other direct and complementary purposes are achieved by the new medicinal and / or food product and / or food supplement and / or probiotic and / or homeopathic product with lysates and / or tindalised bacteria, lysates and / or tindalised mycetes, and in particular with lysates and / or tindalized physiological bacteria or lysates and / or tindalized lactic ferments, such as lactobacillus, bibidobacterium and others, lysates and / or tindalized saccharomycetes and yeasts, to restore and / or maintain the balance of the intestinal bacterial flora and vaginal bacterial flora and for the treatment of disorders in general affecting the gastrointestinal tract and genitourinary mucous membranes.

By lysate or tindalized we mean the rupture of the cell wall of the microbe and its internal corpuscles, such as to determine the biological death effect of the microbial strain and to residue debris of the cell wall, of the cytoplasmic content and of the cell nucleus.

The present invention contains lysates and / or tindalized, obtained both by mechanical, chemical and physical lysis, of bacteria, fungi and spores physiologically or in percentage present significantly at the level of intestinal flora, in particular lysates and / or physiological bacterial tindalized Lactobacillus Lactococcus Leuconostoc Bifidobacterium Saccharomices or lysates and / or tindalized lactic ferments lactobaccilus, Bifidobacterium lysates and / or tindalized Saccharomices, such as for example saccharomyces boulycardiae and saccharomyces or saccharomyces.

Said lysates and / or tindalized are treated in such a way as not to present intrinsic pathogenic effects and in such a way as not to contain biological residues such as to restore the growth of the microbe itself.

The microbial strains from which said lysates and / or tindalized are taken preferably include:

â € ¢ microbial strains normally present in the intestinal bacterial flora and in current probiotic formulations, live or modified, such as gram positive cocci, gram positive bacilli, gram negative aerobes, gram negative anaerobes;

â € ¢ microbial spores;

â € ¢ fungi normally present in the intestinal flora, such as penicillum, candida albicans and other subspecies, yeasts;

â € ¢ protozoa.

It was found that one of the possible effective formulations of the new product involves the association of fungi and physiologically present intestinal bacteria, in the form of lysates and / or tindalized, such as bacteroids, streptococcus, termophilus, lactobacillus acidophilus, bifidobacterium, Saccharomices, etc. , where the composition preferably has a higher dosage of eubiotics and a lower dosage of disbionts.

In particular, the physiological lactic ferments are L-acidophilus, L-Bifidus or Bifidobacterium bifidum, L-brevis, L-buchneri - L-bulgaricus, L-casei, L-cellobiosus or Lactobacillus Fermentum. L- Leichmannii, L- plantarum, Lsalivarius, L-Sporogenes, L-Vaginalis, L- Lactis, Bifidobacterium Lactis, Bifidobacterium Infantis, L- Bifidus Longum, L- Rhamnosus.

The main function of the product is to favor and / or modulate and / or activate and / or inhibit, according to the dosage, similar to a vaccine, the response and the reaction of the immune system of the gastrointestinal tract, of the genitourinary mucosa and of the € ™ respiratory system.

The final effect of the new product is to facilitate and / or inhibit the development of certain microbial strains and the reaction of mucosal surface receptors directly or indirectly involved in contact with the product, such as to simulate a local or systemic response to of the strains used.

The new product is therefore particularly suitable for restoring and / or restoring the balance of the intestinal bacterial flora and the vaginal bacterial flora, for the treatment and / or adjuvant of functional and non-functional disorders of the gastrointestinal and genitourinary system, for the immune modulation of the gastrointestinal and genitourinary system, for the treatment and / or adjuvant of symptoms or disorders secondary to an imbalance of the intestinal and genitourinary bacterial flora, of symptoms or disorders secondary to intestinal dysbiosis, or intestinal dysbiosis, skin blemishes, dermatological symptoms and respiratory symptoms.

Basically, the new product physiologically modulates the local and general immune defenses, both specific and non-specific of the organism. Additional benefits of the new product are the following:

â € ¢ modulation, at the mucosal level, of the concentration of secretory IgA;

â € ¢ modulation of the production of serum IgA, IgG and IgM and in particular increase of the concentration of specific immunoglobulins for the antigens present in the preparation and for the corresponding bacteria or fungi or homologous parasites;

â € ¢ modulation of immune memory by activating specific lymphocytes;

â € ¢ modulation of phagocytosis by macrophages and granulocytes; â € ¢ modulation of the synthesis of interleukin IL-1 and IL-2 and of interferon alpha;

â € ¢ modulation of the cytotoxic activity of N.K. cells (natural killer); â € ¢ modulation of antigen-specific lymphocytes, both at the level of the lymphoid tissue associated with the intestinal mucosa, and in the peripheral blood, due to the fact that the active components of the new product act locally through direct contact with the lymphoid tissue associated with the intestinal mucosa (GALT).

It is expected that the new product, containing said lysates and / or suitably treated tindalysts, can be taken orally, for example as a food supplement in solid form, as soluble tablets or powder, in liquid form, in spray form, in form of yogurt.

Alternatively, the new product is expected to be assimilated by the body through a transdermal or trans mucosa vehicle, such as creams or gels or skin lotions, toothpastes, mouthwashes, gels or creams or vaginal douches.

These are the schematic modalities sufficient for the skilled person to realize the invention, consequently, in concrete application there may be variations without prejudice to the substance of the innovative concept.

Therefore, with reference to the preceding description, the following claims are expressed.

Claims (1)

CLAIMS 1.New product to maintain and / or restore the balance of the intestinal and vaginal bacterial flora and for the treatment of disorders affecting the gastrointestinal tract and genitourinary mucosa, and respiratory mucosa, characterized by the fact of including lysates and / or tindalized lactic ferments and / or lysates and / or tindalized saccharomycetes and / or yeasts physiologically or in percentage significantly present in the organism at the level of intestinal flora and / or genitourinary mucosa and / or respiratory mucosa. 2. New product, as per claim 1, characterized in that said physiological lactic ferments include L-acidophilus, L-Bifidus or Bifidobacterium bifidum, L-brevis, L-buchneri - L-bulgaricus, L-casei, L-cellobiosus or Lactobacillus Fermentum. L- Leichmannii, L- plantarum, L-salivarius, L-Sporogenes, L-Vaginalis, L- Lactis, Bifidobacterium Lactis, Bifidobacterium Infantis, L- Bifidus Longum, L- Rhamnosus. 3. New product, as per claim 1, characterized in that said saccharomycetes and / or yeasts include saccharomyces boulardii and / or saccharomyces cerevisiae and / or aspergillus oryzae. 4. New product, as per the preceding claims, characterized in that said lysates are obtained partially and / or totally by mechanical and / or chemical method. 5.New product, as per the preceding claims, characterized in that said lysates are pulverized and / or solubilized. 6. New product, as per the preceding claims, characterized in that said lysates are obtained partially and / or totally physically. 7.New product, as per the previous claims, characterized by the fact that said tindalized products are obtained partially and / or totally physically 8.New product, as per the preceding claims, characterized in that it is in a solid and / or liquid state and / or in cream and / or gel and / or spray and / or wipes and / or patches. 9. New product, as per the preceding claims, characterized in that it can be assimilated orally, as a food product, medicine and / or food supplement. 10. New product, as per the preceding claims, characterized in that it can be assimilated by transdermal and / or transmucosal way.